『No pain, no gain: Ozempic’s quest for market share』のカバーアート

No pain, no gain: Ozempic’s quest for market share

No pain, no gain: Ozempic’s quest for market share

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices
まだレビューはありません